Core data:
Operating income
Refers to the monetary income obtained by commercial enterprises in selling goods or providing services within a certain period of time. As the source of funds for enterprises to compensate production and operation expenses, the main operating results, the important guarantee of profit and the important part of cash inflow.
Strengthening the management of operating income can encourage enterprises to deeply study and understand the changes of market demand, so as to make correct business decisions and avoid blind production.
Operating income of listed Chinese medicine enterprises in recent five years
Judging from the compound growth of revenue in the past five years, 49 enterprises have achieved positive growth, of which 20 enterprises have increased by more than double digits, and 6 enterprises including Baiyunshan, Pien Tze Huang, Fangsheng Pharmaceutical, Yiling Pharmaceutical, Zhongheng Group and Panlong Pharmaceutical have increased by more than 20%.
Baiyun Mountain has the fastest growth, with a compound revenue growth of 32.46% in the past five years. In recent five years, the lowest revenue was 20.036 billion yuan in 20 16 years, and the highest revenue was 64.952 billion yuan in 20 19 years.
The remaining 15 enterprises all declined, among which five enterprises, such as Shanghai Kaibao, Dong 'e Ejiao, Wanbangde, Angel Pharmaceutical and Kangmei Pharmaceutical, experienced a decline of more than double digits.
Kangmei Pharmaceutical Co., Ltd. suffered the biggest decline, with compound revenue increasing by -29.28% in recent five years. In recent five years, the highest revenue was 2164.2 million yuan in 2065+06, and the lowest was 541200 million yuan in 2020.
gross profit
Refers to the balance of commodity sales income (selling price) of commercial enterprises MINUS the original purchase price of commodities, also known as the difference between purchase and sale of commodities. There are many factors that affect the final profit, and different enterprises vary greatly under different circumstances. Gross profit is considered as the main expenditure of this business.
Its significance lies in that if you don't do this business, some resources will be wasted or still consumed, and profits will become negative; Doing this business may make a profit or reduce losses.
Gross profit of listed Chinese medicine enterprises in recent five years
Judging from the compound growth of gross profit in the past five years, 45 enterprises have achieved positive growth, of which 2/kloc-0 enterprises have increased by more than double digits, and 4 enterprises, including Fangsheng Pharmaceutical, Pien Tze Huang, Zhongheng Group and Yiling Pharmaceutical, have increased by more than 20%.
Fangsheng Pharmaceutical has the fastest growth, with compound gross profit increasing by 32.68% in recent five years. In the past five years, the lowest gross profit was 263 million yuan in 20 16 years, and the highest was 794 million yuan in 2020.
The remaining 19 enterprises all declined, among which six enterprises, including Shanghai Kaibao, Huashen Technology, Dong 'e Ejiao, Yao Ji Holdings, Angel Pharmaceutical and Kangmei Pharmaceutical, experienced a decline of more than double digits.
Kangmei Pharmaceutical Co., Ltd. has the largest decline, with a compound growth rate of -57.35% in the past five years. In recent five years, the highest gross profit was 6.79 billion yuan in 20 17 years, and the lowest was 2140,000 yuan in 2020.
net profit
Refers to the total profit of an enterprise after deducting income tax, that is, the after-tax profit of the enterprise. The amount of net profit depends on two factors, one is the total profit, and the other is the income tax expense.
Net profit is the final result of enterprise management. The more net profit, the better the operating efficiency of the enterprise. If the net profit is small, the operating efficiency of the enterprise will be poor, which is the main index to measure the operating efficiency of the enterprise.
Net profit of listed Chinese medicine enterprises in recent five years
Judging from the compound growth of net profit in the past five years, 30 enterprises have achieved positive growth, of which 18 enterprises have increased by more than double digits, and four enterprises, such as Yisheng Pharmaceutical, Yabao Pharmaceutical, Wohua Pharmaceutical and Pien Tze Huang, have increased by more than 30%.
Yisheng pharmaceutical industry has the fastest growth, with a compound growth rate of 57.50% in the past five years. The lowest net profit in recent five years is 2010.10.30 billion yuan in six years, and the highest is 80 million yuan in 2020.
The remaining 20 companies all experienced declines, among which 9 companies, such as Teyi Pharmaceutical, Kang Hui Pharmaceutical, Jiuzhitang, Shanghai Kaibao, Guizhou Bailing, Guangyuyuan, Huashen Technology, Shenlong Rongfa and Dali Pharmaceutical, experienced declines of more than double digits.
Dali Pharmaceutical Co., Ltd. has the largest decline, with a compound growth rate of -59. 15% in recent five years. In recent five years, the lowest net profit is RMB 30 million in 2020, and the highest is RMB 44 million in 20 17.
Deduct non-net profit
It means that in the process of accounting the company's profits, not only the money related to the company's operating expenses are deducted, but also all expenses unrelated to the operation are deducted during the operation.
After deducting non-net profit from accounting, each company can intuitively see the profitability of a quarter or a year. After deducting the expenses incurred in the course of operation and expenses unrelated to operation, we can see the operating conditions of a company more objectively.
Deduction of Non-net Profit of Listed Chinese Medicine Enterprises in Recent Five Years
Judging from the compound growth of non-net profit deduction in the past five years, 25 enterprises have achieved positive growth, of which 15 enterprises have increased by more than double digits, and 7 enterprises, including Wohua Pharmaceutical, Pien Tze Huang, Jianmin Group, Baiyun Mountain, Yiling Pharmaceutical, Tibet Pharmaceutical and Shouxiangu, have increased by more than 20%.
Wohua Pharmaceutical has the fastest growth, with the compound growth rate of non-net profit deduction reaching 38.45% in recent five years. In recent five years, the lowest deducted non-net profit is 20 18 yuan, and the highest is 2020 169 yuan.
The remaining 17 enterprises all declined, among which 7 enterprises, including Yi Ming Pharmaceutical, Jiuzhitang, Teyi Pharmaceutical, Huashen Technology, Kang Hui Pharmaceutical, Shanghai Kaibao and Guizhou Bailing, experienced a decline of more than double digits.
Guizhou Bailing has the largest decline, with a compound growth rate of -36.72% after deducting non-net profit in recent five years. In recent five years, the lowest non-net profit deducted was 76 million yuan in 2020 and the highest was 555 million yuan in 20 18.
Ranking of Growth Ability of Listed Chinese Medicine Enterprises
Ranking of Growth Ability of Listed Chinese Medicine Enterprises
Tips:
1. The growth ability indicators selected in this paper include the compound growth rate of operating income, gross profit, net profit and non-net profit.
2. The research sample only selects the data of two or more reporting periods after listing, and excludes enterprises with negative indicators. Enterprises that have been listed for only one year will only take the latest data and will not join the research for the time being.
3. In the list of growth ability, the scores of all indicators are converted according to the ratio of 10/64, and the comprehensive score is the average of all indicators. If an indicator has a numerical value but no score (that is, the table is empty), the weight of the indicator will be reduced.
4. Each indicator is only a parameter, and it is also the historical data of the last five years, which can't fully and accurately reflect the future of an enterprise. The content of this article is for data reference only and does not constitute any investment advice.
5. This article refers to the three-level industry classification. Due to the changes in the main business of individual enterprises, the industry classification may be different.